Ranibizumab vs Surabgene lomparvovec

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline

Ranibizumab · Lucentis

Marketed by Roche and partners

Approved in Age-Related Macular Degenerationantibody fragment
Partial signal

NCT00056836 · Phase 3 · completed

The study was randomized and double-masked and enrolled 720 participants, but the registry does not identify the comparator arm or provide results. Because the primary clinical endpoint and whether it was met cannot be verified, the evidence remains limited despite the substantial trial size and controlled design.

Reported efficacy

Losing fewer than 15 letters at 12 months: 94.5% (0.3 mg) and 94.6% (0.5 mg) vs 62.2% sham.

Result source: NCT00056836

Surabgene lomparvovec

Developed by AbbVie and partners

Phase 3 in Age-Related Macular DegenerationAAV gene therapy
Weak signal

NCT04832724 · Phase 2 · completed

The study enrolled 60 participants into sequential RGX-314 dose and formulation groups without randomization, blinding, or a comparator arm. Its primary endpoint was the surrogate pharmacodynamic measure of RGX-314 protein concentration, and no primary outcome results are available.

Next expected readout: December 2026 · NCT04704921 (registry estimate)

Reported efficacy

RGX-314 target protein concentration in aqueous humor (At Week 24): Primary endpoint (aqueous RGX-314 protein at Month 6, high-dose cohorts): 511.7 ng/mL (BRX process, n=14) vs 436.3 ng/mL (HS process, n=14); 80% CI of the difference (-38, 189) overlaps 0 (not_applicable)

Result source: NCT04832724

Results for Age-Related Macular Degeneration

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Ranibizumab: 6 of 6 rows · Surabgene lomparvovec: 5 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRanibizumab
Rows use multiple source trials
Surabgene lomparvovec
BCVA Change Letters
absolute change · ETDRS letters
No placebo or comparator arm
52.9 ETDRS letters @ 52wka,b,c,d
NCT01914159 · Phase 2 · registry result, not featured evidence
-7.6 ETDRS letters @ 106wke,a,b,c,d
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more doses
1.2 ETDRS letters @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
14 ETDRS letters @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
0.9 ETDRS letters @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-3.8 ETDRS letters @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
CRT Change Microns
absolute change · m
No placebo or comparator arm
-158.9 m @ 104wke,f,g,c,h
NCT01972789 · Phase 4 · registry result, not featured evidence
show 1 more dose
-126.9 m @ 104wk
NCT01972789 · Phase 4 · registry result, not featured evidence
-88.6 m @ 106wke,f,g,c,h
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more doses
25.3 m @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
2 m @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-56.7 m @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-108.2 m @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
Dropout rate
10.7%i
NCT02161575 · Phase 4 · registry result, not featured evidence
show 51 more results
23%0.5 mg
NCT01846273 · Phase 4 · registry result, not featured evidence
13.1%0.5 mg + vPDT
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
0%0.5 mg + vPDT
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
—Intensive
NCT01972789 · Phase 4 · registry result, not featured evidence
23%Intensive Retinal Fluid Regimen
NCT01972789 · Phase 4 · registry result, not featured evidence
—Relaxed
NCT01972789 · Phase 4 · registry result, not featured evidence
17.1%Relaxed Retinal Fluid Regimen
NCT01972789 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT02140411 · Phase 4 · registry result, not featured evidence
4.8%Ranibizumab
NCT02140411 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT01986907 · Phase 4 · registry result, not featured evidence
17.3%Ranibizumab
NCT01986907 · Phase 4 · registry result, not featured evidence
6.5%0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
6%0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
20.4%
NCT01810042 · Phase 4 · registry result, not featured evidence
—
NCT01464723 · Phase 4 · registry result, not featured evidence
9.1%50% Fluence PDT
NCT00473642 · Phase 4 · registry result, not featured evidence · combination
20%Ranibizumab
NCT00473642 · Phase 4 · registry result, not featured evidence
20%Standard Fluence PDT
NCT00473642 · Phase 4 · registry result, not featured evidence · combination
5%
NCT02611778 · Phase 3 · registry result, not featured evidence
10%0.5 mg monthly
NCT01748292 · Phase 3 · registry result, not featured evidence
30%0.5 mg treat-and-extend
NCT01748292 · Phase 3 · registry result, not featured evidence
—
NCT02698566 · Phase 3 · registry result, not featured evidence
10.2%0.5 mg treat-and-extend
NCT01948830 · Phase 3 · registry result, not featured evidence
9.8%0.5 mg monthly
NCT01948830 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone0.5 mg
NCT01780935 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone0.5 mg
NCT01780935 · Phase 3 · registry result, not featured evidence
4.4%0.5 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
6.2%0.5 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
5.5%2.0 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
5.8%2.0 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
22.2%Ranibizumab ANCHOR
NCT00331864 · Phase 3 · registry result, not featured evidence
11.3%Ranibizumab Non-ANCHOR
NCT00331864 · Phase 3 · registry result, not featured evidence
19.5%0.5 mg - 3 Times Monthly, Then Quarterly
NCT00275821 · Phase 3 · registry result, not featured evidence
11.7%0.3 mg - 3 Times Monthly, Then Quarterly
NCT00275821 · Phase 3 · registry result, not featured evidence
10.4%0.3 mg Monthly
NCT00275821 · Phase 3 · registry result, not featured evidence
8.3%0.5 mg monthly
NCT00764738 · Phase 2/3 · registry result, not featured evidence
10.7%0.5 mg PRN
NCT00764738 · Phase 2/3 · registry result, not featured evidence
20%2.0 mg monthly
NCT00764738 · Phase 2/3 · registry result, not featured evidence
25%2.0 mg PRN
NCT00764738 · Phase 2/3 · registry result, not featured evidence
10.7%4.0 mg
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
3.2%2.0 mg
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
12.5%
NCT01914159 · Phase 2 · registry result, not featured evidence
10.3%4.0 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
5%0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
21.1%Monotherapy
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
0%Ranibizumab Group 1
NCT00896779 · Phase 2 · registry result, not featured evidence
8.3%Ranibizumab Group 2
NCT00896779 · Phase 2 · registry result, not featured evidence
3.3%1.5 mg / 0.5 mg
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
3.4%0.3 mg / 0.5 mg
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
—high dose
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
—low dose
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
16.7%Cohort 1i
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
0%Cohort 2
NCT03066258 · Phase 1/2 · registry result, not featured evidence
0%Cohort 3
NCT03066258 · Phase 1/2 · registry result, not featured evidence
0%Cohort 4
NCT03066258 · Phase 1/2 · registry result, not featured evidence
8.3%Cohort 5
NCT03066258 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
1.9%i
NCT02161575 · Phase 4 · registry result, not featured evidence
show 51 more results
6.2%0.5 mg
NCT01846273 · Phase 4 · registry result, not featured evidence
5.4%0.5 mg + vPDT
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
0%0.5 mg + vPDT
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
—Intensive
NCT01972789 · Phase 4 · registry result, not featured evidence
6.3%Intensive Retinal Fluid Regimen
NCT01972789 · Phase 4 · registry result, not featured evidence
—Relaxed
NCT01972789 · Phase 4 · registry result, not featured evidence
2.3%Relaxed Retinal Fluid Regimen
NCT01972789 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT02140411 · Phase 4 · registry result, not featured evidence
4.8%Ranibizumab
NCT02140411 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT01986907 · Phase 4 · registry result, not featured evidence
1.2%Ranibizumab
NCT01986907 · Phase 4 · registry result, not featured evidence
3%0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
3%0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
—
NCT01810042 · Phase 4 · registry result, not featured evidence
—
NCT01464723 · Phase 4 · registry result, not featured evidence
—50% Fluence PDT
NCT00473642 · Phase 4 · registry result, not featured evidence · combination
—Ranibizumab
NCT00473642 · Phase 4 · registry result, not featured evidence
—Standard Fluence PDT
NCT00473642 · Phase 4 · registry result, not featured evidence · combination
0.4%
NCT02611778 · Phase 3 · registry result, not featured evidence
10%0.5 mg monthly
NCT01748292 · Phase 3 · registry result, not featured evidence
10%0.5 mg treat-and-extend
NCT01748292 · Phase 3 · registry result, not featured evidence
—
NCT02698566 · Phase 3 · registry result, not featured evidence
2.8%0.5 mg treat-and-extend
NCT01948830 · Phase 3 · registry result, not featured evidence
0.6%0.5 mg monthly
NCT01948830 · Phase 3 · registry result, not featured evidence
0.6%0.5 mg
NCT01780935 · Phase 3 · registry result, not featured evidence
1.2%0.5 mg
NCT01780935 · Phase 3 · registry result, not featured evidence
0.7%0.5 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
0.7%0.5 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
0%2.0 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
0%2.0 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
5.6%Ranibizumab ANCHOR
NCT00331864 · Phase 3 · registry result, not featured evidence
5.8%Ranibizumab Non-ANCHOR
NCT00331864 · Phase 3 · registry result, not featured evidence
10.2%0.5 mg - 3 Times Monthly, Then Quarterly
NCT00275821 · Phase 3 · registry result, not featured evidence
3.3%0.3 mg - 3 Times Monthly, Then Quarterly
NCT00275821 · Phase 3 · registry result, not featured evidence
4.3%0.3 mg Monthly
NCT00275821 · Phase 3 · registry result, not featured evidence
—0.5 mg monthly
NCT00764738 · Phase 2/3 · registry result, not featured evidence
—0.5 mg PRN
NCT00764738 · Phase 2/3 · registry result, not featured evidence
—2.0 mg monthly
NCT00764738 · Phase 2/3 · registry result, not featured evidence
—2.0 mg PRN
NCT00764738 · Phase 2/3 · registry result, not featured evidence
—4.0 mg
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
—2.0 mg
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
—
NCT01914159 · Phase 2 · registry result, not featured evidence
—4.0 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
—0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
—Monotherapy
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
—Ranibizumab Group 1
NCT00896779 · Phase 2 · registry result, not featured evidence
—Ranibizumab Group 2
NCT00896779 · Phase 2 · registry result, not featured evidence
—1.5 mg / 0.5 mg
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
—0.3 mg / 0.5 mg
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
—high dose
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
—low dose
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
—Cohort 1i
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
—Cohort 2
NCT03066258 · Phase 1/2 · registry result, not featured evidence
—Cohort 3
NCT03066258 · Phase 1/2 · registry result, not featured evidence
—Cohort 4
NCT03066258 · Phase 1/2 · registry result, not featured evidence
—Cohort 5
NCT03066258 · Phase 1/2 · registry result, not featured evidence
Serious AEs
10%i
NCT02161575 · Phase 4 · registry result, not featured evidence
show 51 more results
17%0.5 mg
NCT01846273 · Phase 4 · registry result, not featured evidence
15.7%0.5 mg + vPDT
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
14.3%0.5 mg + vPDT
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
33.5%Intensive
NCT01972789 · Phase 4 · registry result, not featured evidence
—Intensive Retinal Fluid Regimen
NCT01972789 · Phase 4 · registry result, not featured evidence
33.3%Relaxed
NCT01972789 · Phase 4 · registry result, not featured evidence
—Relaxed Retinal Fluid Regimen
NCT01972789 · Phase 4 · registry result, not featured evidence
28.6%0.5 mg
NCT02140411 · Phase 4 · registry result, not featured evidence
—Ranibizumab
NCT02140411 · Phase 4 · registry result, not featured evidence
6.7%0.5 mg
NCT01986907 · Phase 4 · registry result, not featured evidence
—Ranibizumab
NCT01986907 · Phase 4 · registry result, not featured evidence
14.5%0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
14.5%0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
4.1%
NCT01810042 · Phase 4 · registry result, not featured evidence
—
NCT01464723 · Phase 4 · registry result, not featured evidence
0%50% Fluence PDT
NCT00473642 · Phase 4 · registry result, not featured evidence · combination
20%Ranibizumab
NCT00473642 · Phase 4 · registry result, not featured evidence
0%Standard Fluence PDT
NCT00473642 · Phase 4 · registry result, not featured evidence · combination
8%
NCT02611778 · Phase 3 · registry result, not featured evidence
35%0.5 mg monthly
NCT01748292 · Phase 3 · registry result, not featured evidence
57.5%0.5 mg treat-and-extend
NCT01748292 · Phase 3 · registry result, not featured evidence
0%
NCT02698566 · Phase 3 · registry result, not featured evidence
12.1%0.5 mg treat-and-extend
NCT01948830 · Phase 3 · registry result, not featured evidence
12.9%0.5 mg monthly
NCT01948830 · Phase 3 · registry result, not featured evidence
9%0.5 mg
NCT01780935 · Phase 3 · registry result, not featured evidence
13.4%0.5 mg
NCT01780935 · Phase 3 · registry result, not featured evidence
20.7%0.5 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
24.1%0.5 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
19.9%2.0 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
19.7%2.0 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
22.2%Ranibizumab ANCHOR
NCT00331864 · Phase 3 · registry result, not featured evidence
15.6%Ranibizumab Non-ANCHOR
NCT00331864 · Phase 3 · registry result, not featured evidence
19.5%0.5 mg - 3 Times Monthly, Then Quarterly
NCT00275821 · Phase 3 · registry result, not featured evidence
12.5%0.3 mg - 3 Times Monthly, Then Quarterly
NCT00275821 · Phase 3 · registry result, not featured evidence
17.4%0.3 mg Monthly
NCT00275821 · Phase 3 · registry result, not featured evidence
0%0.5 mg monthly
NCT00764738 · Phase 2/3 · registry result, not featured evidence
8%0.5 mg PRN
NCT00764738 · Phase 2/3 · registry result, not featured evidence
0%2.0 mg monthly
NCT00764738 · Phase 2/3 · registry result, not featured evidence
0%2.0 mg PRN
NCT00764738 · Phase 2/3 · registry result, not featured evidence
14.3%4.0 mg
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
3.2%2.0 mg
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
0%
NCT01914159 · Phase 2 · registry result, not featured evidence
10.3%4.0 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
10%0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
15.8%Monotherapy
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
0%Ranibizumab Group 1
NCT00896779 · Phase 2 · registry result, not featured evidence
0%Ranibizumab Group 2
NCT00896779 · Phase 2 · registry result, not featured evidence
—1.5 mg / 0.5 mg
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
—0.3 mg / 0.5 mg
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
6.6%high dose
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
9.4%low dose
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
33.3%Cohort 1i
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
33.3%Cohort 2
NCT03066258 · Phase 1/2 · registry result, not featured evidence
16.7%Cohort 3
NCT03066258 · Phase 1/2 · registry result, not featured evidence
25%Cohort 4
NCT03066258 · Phase 1/2 · registry result, not featured evidence
33.3%Cohort 5
NCT03066258 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
i
nasopharyngitis 9%
cough 7%
lower respiratory tract infection 7%
NCT02161575 · Phase 4 · registry result, not featured evidence
show 38 more results
0.5 mg
nasopharyngitis 7.4%
dizziness 3.7%
hypertension 3.7%
NCT01846273 · Phase 4 · registry result, not featured evidence
0.5 mg + vPDT
nasopharyngitis 13.4%
retinal haemorrhage (study eye) 7%
upper respiratory tract infection 7%
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
0.5 mg + vPDT
intraocular pressure increased (study eye) 28.6%
cerumen impaction 14.3%
fasciitis 14.3%
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
eye pain 16.2%
influenza 15%
influenza(non-ocular) 15%
NCT01972789 · Phase 4 · registry result, not featured evidence
nasopharyngitis 16.7%
nasopharyngitis(non-ocular) 16.7%
eye pain 13.8%
NCT01972789 · Phase 4 · registry result, not featured evidence
0.5 mg
oedema peripheral 19%
back pain 9.5%
bronchitis 9.5%
NCT02140411 · Phase 4 · registry result, not featured evidence
0.5 mg
neovascular age-related macular degeneration 3.6%
influenza 1.6%
conjunctival haemorrhage 1.4%
NCT01986907 · Phase 4 · registry result, not featured evidence
0.5 mg monthly
nasopharyngitis 14.5%
conjunctival haemorrhage 12.7%
upper respiratory tract infection 8.4%
NCT01775124 · Phase 4 · registry result, not featured evidence
0.5 mg PRN
nasopharyngitis 10.8%
conjunctival haemorrhage 7.2%
intraocular pressure increased 7.2%
NCT01775124 · Phase 4 · registry result, not featured evidence
neovascular age-related macular degeneration 8%
conjunctival haemorrhage 5.9%
nasopharyngitis 5%
NCT02611778 · Phase 3 · registry result, not featured evidence
0.5 mg monthly
hollenhorst plaque 5%
subretinal hemorrhage 5%
progressive macular atrophy 0%
NCT01748292 · Phase 3 · registry result, not featured evidence
0.5 mg treat-and-extend
progressive macular atrophy 7.5%
subretinal hemorrhage 2.5%
hollenhorst plaque 0%
NCT01748292 · Phase 3 · registry result, not featured evidence
conjunctival hemorrhage 2.9%
NCT02698566 · Phase 3 · registry result, not featured evidence
0.5 mg treat-and-extend
intraocular pressure increased (study eye) 8.4%
hypertension 7.1%
nasopharyngitis 5.6%
NCT01948830 · Phase 3 · registry result, not featured evidence
0.5 mg monthly
intraocular pressure increased (study eye) 8.6%
nasopharyngitis 8%
conjunctival haemorrhage (study eye) 5.8%
NCT01948830 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 7.2%
conjunctival haemorrhage (study eye) 5.7%
hypertension 5.4%
NCT01780935 · Phase 3 · registry result, not featured evidence
0.5 mg
intraocular pressure increased (study eye) 6.3%
hypertension 4.5%
influenza 4.5%
NCT01780935 · Phase 3 · registry result, not featured evidence
0.5 mg as-needed (PRN)
conjunctival haemorrhage 17.5%
sinusitis 9.8%
hypertension 7.6%
NCT00891735 · Phase 3 · registry result, not featured evidence
0.5 mg monthly
conjunctival haemorrhage 23%
vitreous floaters 9.5%
vitreous detachment 8%
NCT00891735 · Phase 3 · registry result, not featured evidence
2.0 mg as-needed (PRN)
conjunctival haemorrhage 15.1%
vitreous detachment 9.9%
eye pain 8.5%
NCT00891735 · Phase 3 · registry result, not featured evidence
2.0 mg monthly
conjunctival haemorrhage 18.6%
eye pain 9.1%
vitreous detachment 8.8%
NCT00891735 · Phase 3 · registry result, not featured evidence
retinal haemorrhage (study eye) 27.8%
choroidal neovascularisation (fellow eye) 11.1%
choroidal neovascularisation (study eye) 11.1%
NCT00331864 · Phase 3 · registry result, not featured evidence
visual acuity reduced (study eye) 18.3%
intraocular pressure increased (study eye) 7%
retinal haemorrhage (study eye) 6.8%
NCT00331864 · Phase 3 · registry result, not featured evidence
0.5 mg - 3 Times Monthly, Then Quarterly
conjunctival haemorrhage (study eye) 16.1%
visual acuity reduced (study eye) 16.1%
eye pain (study eye) 11.9%
NCT00275821 · Phase 3 · registry result, not featured evidence
0.3 mg - 3 Times Monthly, Then Quarterly
conjunctival haemorrhage (study eye) 19.2%
eye pain (study eye) 18.3%
visual acuity reduced (study eye) 12.5%
NCT00275821 · Phase 3 · registry result, not featured evidence
0.3 mg Monthly
eye pain (study eye) 20.9%
intraocular pressure increased (study eye) 14.8%
conjunctival haemorrhage (study eye) 10.4%
NCT00275821 · Phase 3 · registry result, not featured evidence
0.5 mg monthly
injection site irritation 4.5%
corneal abrasion 0%
NCT00764738 · Phase 2/3 · registry result, not featured evidence
0.5 mg PRN
corneal abrasion 4%
injection site irritation 4%
NCT00764738 · Phase 2/3 · registry result, not featured evidence
4.0 mg
conjunctival hyperaemia 14.3% (placebo 0%)
eyelid oedema 10.7% (placebo 0%)
retinal haemorrhage 10.7% (placebo 0%)
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
2.0 mg
eye pain 12.9% (placebo 0%)
conjunctival haemorrhage 9.7% (placebo 11.8%)
retinal haemorrhage 9.7% (placebo 0%)
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
increase of subretinal hemorrhage 4.2%
NCT01914159 · Phase 2 · registry result, not featured evidence
4.0 mg iSONEP
conjunctival haemorrhage 53.8%
intraocular pressure increased 28.2%
vitreous floaters 20.5%
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
0.5 mg iSONEP
conjunctival haemorrhage 60%
activated partial thromboplastin time prolonged 12.5%
vitreous floaters 12.5%
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
conjunctival haemorrhage 34.2%
retinal haemorrhage 28.9%
arthralgia 7.9%
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
bruised sturnum 12.5%
development of choroidal neovascularization - fellow eye 12.5%
intestinal flu 12.5%
NCT00896779 · Phase 2 · registry result, not featured evidence
ache left eye - treatment eye 8.3%
cold 8.3%
corneal abrasion - both eyes 8.3%
NCT00896779 · Phase 2 · registry result, not featured evidence
high dose
conjunctival hemorrhage 33.6%
punctate keratitis 9.9%
conjunctival hyperemia 8.6%
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
low dose
conjunctival hemorrhage 22.8%
punctate keratitis 12.8%
eye pain 6.7%
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
i
intraocular inflammation 66.7%
retinal haemorrhage 66.7%
visual acuity reduced/impairment 50%
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
conjunctival haemorrhage 50%
intraocular inflammation 50%
retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 50%
NCT03066258 · Phase 1/2 · registry result, not featured evidence
conjunctival haemorrhage 66.7%
intraocular inflammation 50%
retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 50%
NCT03066258 · Phase 1/2 · registry result, not featured evidence
retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 100%
conjunctival haemorrhage 75%
retinal thickening 33.3%
NCT03066258 · Phase 1/2 · registry result, not featured evidence
conjunctival haemorrhage 91.7%
retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 91.7%
eye irritation 33.3%
NCT03066258 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 1/2 versus Phase 2.
  2. bPopulation context differs: registered conditions differ.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 106 weeks versus 52 weeks.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fTrial phases differ: Phase 1/2 versus Phase 4.
  7. gPopulation comparability has not been reviewed for both studies.
  8. hAssessment timepoints differ: 106 weeks versus 104 weeks.
  9. iPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ranibizumab

Dry Retina Resolution 0% (n=100) @ 25.7wk
event count · % of participants
No placebo or comparator arm
Day 180 · Yes, Definitive
NCT02161575 · Phase 4 · registry result, not featured evidence · converted to % from 0 Participants as posted
BCVA Change Letters 5.1 Letters @ 52wk0.5 mg
absolute change · Letters
No placebo or comparator arm
NCT01846273 · Phase 4 · registry result, not featured evidence
show 25 more results
5.4 Letters @ 104wk0.5 mg
NCT01846273 · Phase 4 · registry result, not featured evidence
3.3 Letters0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
1.7 Letters0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
3.7 Letters0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
2.2 Letters0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
10.1 Letters @ 52wk0.5 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
8.2 Letters @ 52wk0.5 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
9.2 Letters @ 52wk2.0 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
8.6 Letters @ 52wk2.0 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
8.3 Letters @ 52wk0.5 mg + vPDT
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
9.7 Letters @ 104wk0.5 mg + vPDT
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
6.1 Letters @ 104wk0.5 mg + vPDT
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
3.2 Letters @ 104wk
NCT01972789 · Phase 4 · registry result, not featured evidence
2.5 Letters @ 104wk
NCT01972789 · Phase 4 · registry result, not featured evidence
4.6 Letters @ 52wk
NCT01972789 · Phase 4 · registry result, not featured evidence
3.9 Letters @ 52wk
NCT01972789 · Phase 4 · registry result, not featured evidence
9.55 Letters @ 48wk
NCT02140411 · Phase 4 · registry result, not featured evidence
5.65 Letters @ 4wk
NCT02140411 · Phase 4 · registry result, not featured evidence
6.9 Letters @ 8wk
NCT02140411 · Phase 4 · registry result, not featured evidence
8.5 Letters @ 12wk
NCT02140411 · Phase 4 · registry result, not featured evidence
8.05 Letters @ 24wk
NCT02140411 · Phase 4 · registry result, not featured evidence
8.4 Letters @ 36wk
NCT02140411 · Phase 4 · registry result, not featured evidence
5.9 Letters @ 52wk
NCT00473642 · Phase 4 · registry result, not featured evidence · combination
7.6 Letters @ 52wk
NCT00473642 · Phase 4 · registry result, not featured evidence · combination
16.4 Letters @ 52wk
NCT00473642 · Phase 4 · registry result, not featured evidence · monotherapy
Complete Polyp Regression 33.8% (n=154) @ 52wk0.5 mg
event count · % of participants
No placebo or comparator arm
NCT01846273 · Phase 4 · registry result, not featured evidence · converted to % from 52 Participants as posted
show 1 more result
68.5% (n=168) @ 52wk*0.5 mg + vPDT
NCT01846273 · Phase 4 · registry result, not featured evidence · combination · converted to % from 115 Participants as posted
Complete Polyp Regression 30.4% (n=113) @ 26wk0.5 mg
responder rate · % of participants
No placebo or comparator arm
Month 6 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence
show 2 more results
71.3% (n=168) @ 26wk0.5 mg + vPDT
Month 6 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
22% (n=41) @ 26wk0.5 mg + vPDT
Month 6 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
Complete Polyp Regression 26.7% (n=113) @ 104wk0.5 mg
responder rate · % of participants
No placebo or comparator arm
Month 24 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence
show 2 more results
56.6% (n=168) @ 104wk0.5 mg + vPDT
Month 24 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
47.5% (n=41) @ 104wk0.5 mg + vPDT
Month 24 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
Active CNV Leakage 73.5% (n=113) @ 26wk0.5 mg
responder rate · % of participants
No placebo or comparator arm
Month 6 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence
show 2 more results
43% (n=168) @ 26wk0.5 mg + vPDT
Month 6 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
78% (n=41) @ 26wk0.5 mg + vPDT
Month 6 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
Absence of Leakage 26.5% (n=113) @ 26wk0.5 mg
responder rate · % of participants
No placebo or comparator arm
Month 6 - No
NCT01846273 · Phase 4 · registry result, not featured evidence
show 2 more results
55.1% (n=168) @ 26wk0.5 mg + vPDT
Month 6 - No
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
22% (n=41) @ 26wk0.5 mg + vPDT
Month 6 - No
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
Active CNV Leakage 72.6% (n=113) @ 52wk0.5 mg
responder rate · % of participants
No placebo or comparator arm
Month 12 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence
show 2 more results
47.7% (n=168) @ 52wk0.5 mg + vPDT
Month 12 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
80.5% (n=41) @ 52wk0.5 mg + vPDT
Month 12 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
Absence of Leakage 27.4% (n=113) @ 52wk0.5 mg
responder rate · % of participants
No placebo or comparator arm
Month 12 - No
NCT01846273 · Phase 4 · registry result, not featured evidence
show 2 more results
51.6% (n=168) @ 52wk0.5 mg + vPDT
Month 12 - No
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
19.5% (n=41) @ 52wk0.5 mg + vPDT
Month 12 - No
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
Active CNV Leakage 65.1% (n=113) @ 104wk0.5 mg
responder rate · % of participants
No placebo or comparator arm
Month 24 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence
show 2 more results
56.8% (n=168) @ 104wk0.5 mg + vPDT
Month 24 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
56.1% (n=41) @ 104wk0.5 mg + vPDT
Month 24 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
Absence of Leakage 34.9% (n=113) @ 104wk0.5 mg
responder rate · % of participants
No placebo or comparator arm
Month 24 - No
NCT01846273 · Phase 4 · registry result, not featured evidence
show 2 more results
40.4% (n=168) @ 104wk0.5 mg + vPDT
Month 24 - No
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
39% (n=41) @ 104wk0.5 mg + vPDT
Month 24 - No
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
NEI VFQ-25 Total 4.6 score @ 13wk0.5 mg
absolute change · score
No placebo or comparator arm
Month 3 - Change from Baseline
NCT01846273 · Phase 4 · registry result, not featured evidence
show 2 more results
2.9 score @ 13wk0.5 mg + vPDT
Month 3 - Change from Baseline
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
1.7 score @ 13wk0.5 mg + vPDT
Month 3 - Change from Baseline
NCT01846273 · Phase 4 · registry result, not featured evidence · combination

+ 58 further endpoints in the CSV export.

Surabgene lomparvovec

Supplemental Injection Rate Annualized 10.3 per year @ 106wk
event rate · per year
No placebo or comparator arm
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
9.3 per year @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
2.8 per year @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
4.4 per year @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
2 per year @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
CNV Area Change Mm2 -0.4 mm @ 106wk
absolute change · mm
No placebo or comparator arm
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
0 mm @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-1.2 mm @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-1.1 mm @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-0.6 mm @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ranibizumab's landscape · Surabgene lomparvovec's landscape